The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.

[1]  R. Califf,et al.  Early versus delayed, provisional eptifibatide in acute coronary syndromes. , 2009, The New England journal of medicine.

[2]  Marc P. Bonaca,et al.  Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. , 2009, American heart journal.

[3]  K. Mahaffey,et al.  Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study , 2009, The Lancet.

[4]  Angelo Branzi,et al.  Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: the task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. , 2007, European heart journal.

[5]  William Wijns,et al.  [Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]. , 2007, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[6]  J. Alpert,et al.  Universal definition of myocardial infarction. , 2007, European heart journal.

[7]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[8]  J. Ornato,et al.  ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patie , 2007, Journal of the American College of Cardiology.

[9]  Adelaide,et al.  Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.

[10]  A. Leger,et al.  Protease-Activated Receptors in Cardiovascular Diseases , 2006, Circulation.

[11]  S. Yusuf,et al.  Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes , 2006, Circulation.

[12]  Patrice Cacoub,et al.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.

[13]  Deepak L. Bhatt,et al.  Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. , 2006, Archives of internal medicine.

[14]  A. Kastrati,et al.  Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. , 2006, JAMA.

[15]  Robert M Califf,et al.  A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. , 2006, Journal of the American College of Cardiology.

[16]  R. Califf,et al.  High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. , 2005, JAMA.

[17]  R. Califf,et al.  Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. , 2005, The American journal of cardiology.

[18]  A. Skene,et al.  Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. , 2005, The New England journal of medicine.

[19]  Nicola J Cooper,et al.  A Bayesian approach to evaluating net clinical benefit allowed for parameter uncertainty. , 2005, Journal of clinical epidemiology.

[20]  Sunil V. Rao,et al.  Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. , 2004, JAMA.

[21]  F. Fauvel-Lafève,et al.  Platelet adhesion and signaling induced by the octapeptide primary binding sequence (KOGEOGPK) from type III collagen , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  R. Califf,et al.  Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. , 2004, JAMA.

[23]  A. Laupacis,et al.  Age, risk-benefit trade-offs, and the projected effects of evidence-based therapies , 2004 .

[24]  M. Takano,et al.  Elevated Troponin T Levels and Lesion Characteristics in Non–ST-Elevation Acute Coronary Syndromes , 2004, Circulation.

[25]  R. Califf,et al.  Inhibition of Platelet Aggregation with a Glycoprotein IIb-IIIa Antagonist Does Not Prevent Thrombin Generation in Patients Undergoing Thrombolysis for Acute Myocardial Infarction , 2004, Journal of Thrombosis and Thrombolysis.

[26]  J. Seki,et al.  Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. , 2003, European journal of pharmacology.

[27]  M. D'Andrea,et al.  Blockade of the Thrombin Receptor Protease-Activated Receptor-1 with a Small-Molecule Antagonist Prevents Thrombus Formation and Vascular Occlusion in Nonhuman Primates , 2003, Journal of Pharmacology and Experimental Therapeutics.

[28]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[29]  S. Yusuf,et al.  Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. , 2002, European heart journal.

[30]  K. Eagle,et al.  Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). , 2002, The American journal of cardiology.

[31]  M. Anderluh,et al.  Thrombin receptor antagonists; recent advances in PAR-1 antagonist development. , 2002, Current medicinal chemistry.

[32]  S. Goto,et al.  Functional Significance of Adenosine 5′-Diphosphate Receptor (P2Y12) in Platelet Activation Initiated by Binding of von Willebrand Factor to Platelet GP Ib&agr; Induced by Conditions of High Shear Rate , 2002, Circulation.

[33]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[34]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[35]  K Fujikawa,et al.  Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. Doller,et al.  Design, synthesis, and structure-activity relationship studies of himbacine derived muscarinic receptor antagonists. , 1999, Bioorganic & medicinal chemistry letters.

[37]  R. Davies,et al.  A Highly Efficient Total Synthesis of (+)-Himbacine , 1996 .

[38]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.